Acrivon is proud to support the Termeer Foundation and its mission to “vibrantly connect and empower the world of healthcare innovators until every patient has a cure.” Thank you, Belinda Termeer for your bold leadership.
Acrivon Therapeutics, Inc.
Biotechnology Research
Cambridge, Massachusetts 3,524 followers
About us
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Leveraging our unique patient selection platform, Acrivon Therapeutics aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. Acrivon Therapeutics and its clinical biomarker development group is headquartered in the greater Boston area, with biomarker discovery efforts concentrated in our wholly-owned subsidiary in Lund, Sweden.
- Website
-
https://acrivon.com
External link for Acrivon Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Proteomics, Drug development, Multiplex tissue imaging, Biomarker discovery, Precision Medicine, Oncology, and Therapeutics
Locations
-
Primary
Get directions
700 North Main Street
Cambridge, Massachusetts 02139, US
-
Get directions
Medicon Village
Lund, SE
Employees at Acrivon Therapeutics, Inc.
Updates
-
According to the American Association for Cancer Research (AACR), more than 18 million people in the US and millions more worldwide are cancer survivors due to advances made by cancer research. We appreciate our employees and all others dedicated to finding cures. #NCRM24
-
-
We are passionate about science and about all living things. That’s why our teams from both sites – in Lund, Sweden and Watertown, MA – enthusiastically cleaned up our neighborhoods to support Mother Earth. #GlobalVolunteerMonth
-
-
Today, we are presenting initial positive clinical data with ACR-368 from the ongoing Phase 2 trial which demonstrated prospective validation of our proprietary ACR-368 OncoSignature patient selection biomarker test, as well as new preclinical data and accelerated IND timeline for ACR-2316. Join the webcast: https://lnkd.in/gBFGjTa6. Find out more: https://lnkd.in/dXWF4Mn9
-
-
Our poster presentations at #AACR24 were very well-received! Thank you for the significant interest in our innovative AP3 platform and promising programs. If you missed it, you can read more in our press release at: https://lnkd.in/gFWy4QYm and view our posters at: https://lnkd.in/gStqjybY
-
“With this funding, we are well positioned to continue the advancement of our lead clinical asset, ACR-368, currently in registrational-intent Phase 2 trials, as well as our preclinical pipeline including ACR-2316, our internally-discovered, novel WEE1/PKMYT1 inhibitor and our recently declared cell cycle regulatory program with an undisclosed target. I am particularly excited about the enthusiasm for the broad potential of Acrivon’s differentiated AP3 platform and the support for our compelling long-term strategy aiming to transform precision medicine for the benefit of patients,” said CEO Peter Blume-Jensen. Find out more: https://lnkd.in/ex_gDF7g
Acrivon Therapeutics Announces $130 Million Private Placement Financing | Acrivon Therapeutics, Inc.
ir.acrivon.com
-
The data we will be presenting reinforce the broad applicability of our highly differentiated, actionable AP3 platform technology -- including the potential to generate selective, potent single-agent active molecules, as well as possibly prevent or reduce drug resistance by uncovering and overcoming underlying resistance mechanisms. Find out more: https://lnkd.in/ehCeu8aJ
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 | Acrivon Therapeutics, Inc.
ir.acrivon.com
-
We hope to see you in Boston for the TD Cowen Health Care Conference. For those not attending, you can access a webcast of the panel discussion on our website at: https://lnkd.in/gBFGjTa6
Events & Presentations | Acrivon Therapeutics, Inc.
ir.acrivon.com
-
We are excited to welcome Santhosh Palani, Ph.D., CFA, to our board. He is uniquely qualified, having served on numerous boards in the past, providing his extensive expertise as a successful private and public healthcare investor as well as a drug developer earlier in his career. Read more here: https://lnkd.in/dFaFAzRE
News Releases | Acrivon Therapeutics, Inc.
ir.acrivon.com
-
Join the webcast to hear our CEO Peter discuss the latest on Acrivon and our pipeline of targeted precision oncology medicines at the Oppenheimer Healthcare Conference by accessing it here: https://lnkd.in/gBFGjTa6
Events & Presentations | Acrivon Therapeutics, Inc.
ir.acrivon.com